ADMS Adamas Pharmaceuticals Inc.

9.3
-0.18  -2%
Previous Close 9.48
Open 9.39
Price To Book 2.23
Market Cap 254220457
Shares 27,335,533
Volume 594,559
Short Ratio
Av. Daily Volume 669,554

NewsSee all news

  1. Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
  2. Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT
  3. Adamas to Present at Three November Investor Conferences
  4. Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth
  5. The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today

SEC filingsSee all SEC filings

  1. 8-K - Current report 181153661
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153638
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181115101
  4. 8-K - Current report 181108029
  5. 8-K - Current report 181082698

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 3 commencement of enrollment announced April 3, 2018. Enrollment to be completed 2H 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
  2. Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT
  3. Adamas to Present at Three November Investor Conferences
  4. Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth
  5. The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today
  6. Adamas: 3Q Earnings Snapshot
  7. Adamas Reports Third Quarter 2018 Financial Results
  8. The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
  9. Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
  10. China cutting rare earth output, unnerving global manufacturers
  11. Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals — Fundamental Analysis, Key Performance Indications
  12. Why Adamas Pharmaceuticals, Inc. Stock Sank in September
  13. Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
  14. Adamas Announces New Employment Inducement Grant
  15. When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)?
  16. Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
  17. A Financial Overview of Supernus Pharmaceuticals in September
  18. Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

SEC Filings

  1. 8-K - Current report 181153661
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153638
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181115101
  4. 8-K - Current report 181108029
  5. 8-K - Current report 181082698
  6. 8-K - Current report 181071292
  7. 8-K - Current report 18988307
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988220
  9. 8-K - Current report 18884052
  10. 8-K - Current report 18803788